Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company is advancing a diverse pipeline of therapeutic candidates through pivotal clinical trials, addressing critical unmet needs in neurology. With a seasoned management team and strategic partnerships, Neurosense is poised to develop groundbreaking therapies that not only enhance patient outcomes but also bolster its competitive position in the biopharmaceutical sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.07M |
| Operating Margin | 0.00% |
| Return on Equity | -2175.00% |
| Return on Assets | -247.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.05 |
| Price-to-Book | 2.64 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.10M |
| Float | $23.34M |
| % Insiders | 32.30% |
| % Institutions | 0.96% |
Volatility is currently contracting
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward CAMBRIDGE, Mass.
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progression PrimeC demonstrates target engagement with consistent effects across clinical outcomes, survival, and biomarkers, supporting its potential as a disease-modifying therapy CAMBRIDGE, Mass., June 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings support continued development of PrimeC's multi-target approach in Alzheimer's disease CAMBRIDGE, Mass., June 25, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC CAMBRIDGE, Mass., June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NRSN and any ticker you trade — then tracks every position and per-strategy win rate.
